MX2023008423A - Anticuerpos anti-gremlin1 novedosos. - Google Patents
Anticuerpos anti-gremlin1 novedosos.Info
- Publication number
- MX2023008423A MX2023008423A MX2023008423A MX2023008423A MX2023008423A MX 2023008423 A MX2023008423 A MX 2023008423A MX 2023008423 A MX2023008423 A MX 2023008423A MX 2023008423 A MX2023008423 A MX 2023008423A MX 2023008423 A MX2023008423 A MX 2023008423A
- Authority
- MX
- Mexico
- Prior art keywords
- gremlin1
- antibodies
- novel anti
- same
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021072397 | 2021-01-18 | ||
| CN2021142043 | 2021-12-28 | ||
| PCT/CN2022/072297 WO2022152290A1 (en) | 2021-01-18 | 2022-01-17 | Novel anti-gremlin1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008423A true MX2023008423A (es) | 2023-07-26 |
Family
ID=82446960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008423A MX2023008423A (es) | 2021-01-18 | 2022-01-17 | Anticuerpos anti-gremlin1 novedosos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240294622A1 (enExample) |
| EP (1) | EP4277927A4 (enExample) |
| JP (1) | JP7879131B2 (enExample) |
| KR (1) | KR20230132544A (enExample) |
| CN (1) | CN116848135A (enExample) |
| AU (1) | AU2022207030A1 (enExample) |
| CA (1) | CA3208455A1 (enExample) |
| MX (1) | MX2023008423A (enExample) |
| TW (1) | TW202241944A (enExample) |
| WO (1) | WO2022152290A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230156936A (ko) * | 2021-03-11 | 2023-11-15 | 상하이 지아오통 대학 | 그렘린1 길항제를 사용하여 질환을 치료하는 방법 |
| GB202205203D0 (en) * | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
| GB202205200D0 (en) * | 2022-04-08 | 2022-05-25 | Ucb Biopharma Sprl | Combination with chemotherapy |
| KR20250169623A (ko) * | 2023-04-13 | 2025-12-03 | 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 | 암 치료를 위한 grem1 길항제를 수반하는 조합 요법 |
| TW202541848A (zh) * | 2024-01-08 | 2025-11-01 | 中國大陸商蘇州創勝醫藥集團有限公司 | 用於治療ｐａｈ之ｇｒｅｍ１拮抗劑及活化素受體拮抗劑的組合療法 |
| CN117801109B (zh) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成内皮祖细胞的方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013137686A1 (ko) | 2012-03-15 | 2013-09-19 | 서울대학교 산학협력단 | 그렘린-1에 대한 항체 |
| BR112015021979A2 (pt) * | 2013-03-14 | 2017-08-29 | Regeneron Pharma | Anticorpos humanos para grem1 |
| CN109641954A (zh) | 2016-08-29 | 2019-04-16 | 里珍纳龙药品有限公司 | 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法 |
| GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| AU2019289176B2 (en) | 2018-06-18 | 2026-02-19 | Adelaide university | Gremlin-1 antagonist for the prevention and treatment of cancer |
| KR20230156936A (ko) * | 2021-03-11 | 2023-11-15 | 상하이 지아오통 대학 | 그렘린1 길항제를 사용하여 질환을 치료하는 방법 |
-
2022
- 2022-01-17 AU AU2022207030A patent/AU2022207030A1/en active Pending
- 2022-01-17 MX MX2023008423A patent/MX2023008423A/es unknown
- 2022-01-17 WO PCT/CN2022/072297 patent/WO2022152290A1/en not_active Ceased
- 2022-01-17 US US18/261,834 patent/US20240294622A1/en active Pending
- 2022-01-17 EP EP22739165.3A patent/EP4277927A4/en active Pending
- 2022-01-17 KR KR1020237027807A patent/KR20230132544A/ko active Pending
- 2022-01-17 CN CN202280010207.XA patent/CN116848135A/zh active Pending
- 2022-01-17 JP JP2023543120A patent/JP7879131B2/ja active Active
- 2022-01-17 CA CA3208455A patent/CA3208455A1/en active Pending
- 2022-01-18 TW TW111102041A patent/TW202241944A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024504124A (ja) | 2024-01-30 |
| CA3208455A1 (en) | 2022-07-21 |
| JP7879131B2 (ja) | 2026-06-23 |
| US20240294622A1 (en) | 2024-09-05 |
| EP4277927A1 (en) | 2023-11-22 |
| EP4277927A4 (en) | 2025-07-23 |
| AU2022207030A9 (en) | 2024-09-19 |
| AU2022207030A1 (en) | 2023-08-24 |
| TW202241944A (zh) | 2022-11-01 |
| KR20230132544A (ko) | 2023-09-15 |
| CN116848135A (zh) | 2023-10-03 |
| WO2022152290A1 (en) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3149406A1 (en) | Novel anti-cldn18.2 antibodies | |
| MX2022007959A (es) | Nuevos anticuerpos anti-fgfr2b. | |
| MX2024007966A (es) | Anticuerpos anti-tslp novedosos. | |
| MX2022007961A (es) | Nuevos anticuerpos anti-fgfr2b. | |
| WO2021183839A3 (en) | Novel anti-lilrb4 antibodies and derivative products | |
| CR20230581A (es) | Anticuerpos anti-CCR8 y usos de los mismos | |
| ZA202311412B (en) | Anti-phf-tau antibodies and uses thereof | |
| MX2022007960A (es) | Nuevos anticuerpos anti-fgfr2b. | |
| MX2025009320A (es) | Anticuerpos anti-cd19 novedosos | |
| WO2020039321A3 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| PH12020550078A1 (en) | Novel anti-cd3epsilon antibodies | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| WO2017106684A3 (en) | Antibodies specifically binding hla-dr and their uses | |
| ZA202309516B (en) | Anti-ccr8 antibodies | |
| WO2020260898A3 (en) | Novel cancer antigens and methods | |
| WO2021207433A3 (en) | Epitopes of sars-cov-2 neutralizing antibodies | |
| EP4273165A3 (en) | Interferon beta antibodies and uses thereof | |
| WO2018227063A8 (en) | Anti-robo2 antibodies, compositions, methods and uses thereof | |
| MX2024011805A (es) | Nuevos anticuerpos anti-fgfr2 | |
| MX2021010766A (es) | Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos. | |
| WO2021207948A9 (en) | Anti-sars-cov-2 antibodies and uses thereof | |
| WO2020073835A8 (zh) | 白介素-6的人源化单克隆抗体、其编码基因及应用 | |
| MX2020010092A (es) | Variantes de anticuerpo c-terminales. |